- Home
- PLRX
as 12-17-2024 4:00pm EST
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 641.5M | IPO Year: | 2020 |
| Target Price: | $40.50 | AVG Volume (30 days): | 459.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.22 - $19.62 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | -83.69% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Pliant Therapeutics Inc. News
PLRX Breaking Stock News: Dive into PLRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Pliant Therapeutics to Participate in Upcoming Investor Events
GlobeNewswire
a month ago
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
GlobeNewswire
a month ago
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire
a month ago
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
GlobeNewswire
2 months ago
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024
GuruFocus.com
2 months ago
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc
GlobeNewswire
3 months ago
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
GlobeNewswire
3 months ago
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Compare PLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PLRX Pliant Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.